Email Address:
  
  Password:
  
  

Exhibit 10.20

CONFIDENTIAL TREATMENT REQUESTED

WITH RESPECT TO CERTAIN PORTIONS HEREOF

DENOTED WITH “***”

AMENDMENT

TO

CLINICAL DEVELOPMENT AND LICENSE AGREEMENT

This Amendment (this “ Amendment ”) to the Clinical Development and License Agreement, dated as of July 14, 2005 (as amended from time to time, the “ CDC License ”), is dated as of September 5, 2007, by and among CDC IV, LLC (“ CDC ”), BioDelivery Sciences International, Inc. (“ BioDelivery ”), Arius Pharmaceuticals, Inc., a wholly-owned subsidiary of BioDelivery (“ Arius ”) and Arius Two, Inc., a wholly-owned subsidiary of BioDelivery (“ Arius Two ” and together with Arius and BioDelivery, collectively, the “ Company ”). Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the CDC License.

RECITALS

WHEREAS, CDC (as successor in interest to Clinical Development Capital LLC), BioDelivery, Arius and Arius Two entered into the CDC License, pursuant to which, among other things, CDC invested in the development of certain compounds being developed by the Company;

WHEREAS, the Company and Arius have entered into that certain License and Development Agreement, dated as of the date hereof, with Meda AB (“ Meda ”), a Swedish corporation (the “ Meda Agreement ”), granting Meda rights to develop and commercialize the BEMA Fentanyl product in the United States, Canada, and Mexico; and

WHEREAS, CDC and the Company desire to amend the CDC License to coordinate certain of the terms of the CDC License with the Meda Ag


This is only a partial view of this document. We have millions of legal documents and clauses drafted by top law firms. learn more search for free browse for free learn more